STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-169)	PRALUZATAMAB RAVTANSINE
PRONUNCIATION	pral” ue zat’ a mab rav tan’ seen
THERAPEUTIC CLAIM	Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human activated leukocyte cell adhesion molecule) (human monoclonal CX-191 γ1-chain), disulfide with prodomain protein (synthetic masking moiety and cleavable moiety protease substrate-containing) fusion protein with human monoclonal CX-191 κ-chain, dimer (Source: CAS)

2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* CD166 antigen (Activated leukocyte cell adhesion molecule)); humanized monoclonal antibody; γ1 heavy chain humanized (1-450) [VH (*Homo sapiens* IGHV2-5*01 (89%) –(IGHD)-IGHJ4*01 (93%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03 {CH1[R^{97}>K(217)], CH3[K^{107}>del(451)]} (122-450)], (224-270')-disulfide with κ light chain humanized (1'-270') {*N*-terminal region [synthetic masking moiety-(1'-22')- triglycyldiseryldiglycylseryl linker-(23'-30')- cleavable moiety protease substrate-containing -(31'-48')- diglycylseryl linker (49'-51')]}-(1'-51')-[humanized V-KAPPA (*Mus musculus* IGKV2-109*01 (91%) –IGKJ2*03 (92%):*Homo sapiens* IGKV2-28*01 (89%) –IGKJ2*01)-[11.3.9] (52'-163') -*Homo sapiens* IGKC*01 (164'-270')], dimer (230-230":233-233")-bisdisulfide, substituted on N^6 of 3 to 4 lysyl residues by the radical ravtasine: 4-[(5-{[(2*S*)-1-{[(1*S*,2*R*,3*S*,5*S*,6*S*,16*E*,18*E*,20*R*,21*S*)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.$1^{10,14}$.$0^{3,5}$]hexacosa-1,12,14(26),16,18-pentaene-6-yl]oxy}-1-oxopropan-2-yl](methyl)amino}-2-methyl-5-oxopentan-2-yl)disulfanyl]butanoyl (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA

Heavy chain X & X"

```
QITLKESGPT  LVKPTQTLTL  TCTFSGFSLS  TYGMGVGWIR  QPPGKALEWL   50
ANIWWSEDKH  YSPSLKSRLT  ITKDTSKNQV  VLTITNVDPV  DTATYYCVQI  100
DYGNDYAFTY  WGQGTLVTVS  SASTKGPSVF  PLAPSSKSTS  GGTAALGCLV  150
KDYFPEPVTV  SWNSGALTSG  VHTFPAVLQS  SGLYSLSSVV  TVPSSSLGTQ  200
TYICNVNHKP  SNTKVDKKVE  PKSCDKTHTC  PPCPAPELLG  GPSVFLFPPK  250
PKDTLMISRT  PEVTCVVVDV  SHEDPEVKFN  WYVDGVEVHN  AKTKPREEQY  300
NSTYRVVSVL  TVLHQDWLNG  KEYKCKVSNK  ALPAPIEKTI  SKAKGQPREP  350
QVYTLPPSRE  EMTKNQVSLT  CLVKGFYPSD  IAVEWESNGQ  PENNYKTTPP  400
VLDSDGSFFL  YSKLTVDKSR  WQQGNVFSCS  VMHEALHNHY  TQKSLSLSPG  450
```

Light chain X' & X'"

```
QGQSGQGLCH  PAVLSAWESC  SSGGGSSGGS  AVGLLAPPGG  LSGRSDNHGG   50'
SDIVMTQSPL  SLPVTPGEPA  SISCRSSKSL  LHSNGITYLY  WYLQKPGQSP  100'
QLLIYQMSNL  ASGVPDRFSG  SGSGTDFTLK  ISRVEAEDVG  VYYCAQNLEL  150'
PYTFGQGTKL  EIKRTVAAPS  VFIFPPSDEQ  LKSGTASVVC  LLNNFYPREA  200'
KVQWKVDNAL  QSGNSQESVT  EQDSKDSTYS  LSSTLTLSKA  DYEKHKVYAC  250'
EVTHQGLSSP  VTKSFNRGEC                                     270'
```

Modified residues

K
an average of 3 to 4 out of 94 lysyl residues are N^6 substituted by ravtansine radical



Disulfide bridges location

9'-20'	9'''-20'''	22-97	22''-97''	74'-144'	74'''-144'''
148-204	148''-204''	190'-250'	190'''-250'''	224-270'	224''-270'''
230-230''	233-233''	265-325	265''-328''	371-429	371''-429''

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-301 Asn-301''

MOLECULAR FORMULA	$C_{6942}H_{10740}N_{1828}O_{2176}S_{48}$. $(C_{42}H_{58}ClN_3O_{11}S_2)_n$ (non glcosylated) n = an average of 3 to 4
MOLECULAR WEIGHT	~159.2 kDa
TRADEMARK	None as yet
SPONSOR	CytomX Therapeutics Inc.
CODE DESIGNATIONS	CX-2009
CAS REGISTRY NUMBER	2145115-85-9
UNII	RD2I59M9FC
WHO NUMBER	10939

gbk